HOME > LATEST
LATEST
-
REGULATORY Japan Moves to Bypass Wholesalers in Fuel Supply to Hospitals
April 10, 2026
-
REGULATORY Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
-
REGULATORY Briviact Set for Price Cut with CEA Adjustment Rate of 0.1
April 9, 2026
-
REGULATORY Chuikyo Sets Reimbursement Pathways for Five Regenerative Medicine Products
April 9, 2026
-
BUSINESS Pfizer Japan Files Tukysa Label Expansion in Breast, Biliary Tract Cancers
April 9, 2026
-
ACADEMIA Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
-
BUSINESS Shionogi Signs US Government Contract to Boost Cefiderocol Supply
April 9, 2026
-
BUSINESS Sumitomo Pharma to Raise up to 116.5 Billion Yen for R&D, Debt Reduction
April 9, 2026
-
REGULATORY Chuikyo Names Hosei Prof. Sugahara to Drug Pricing, CEA Panels
April 9, 2026
-
BUSINESS Meiji Pharma Asia Launches Operations in Singapore
April 9, 2026
-
BUSINESS Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
-
BUSINESS BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
-
ORGANIZATION Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
-
REGULATORY MHLW Publishes Updated LLP List with Higher Surcharges from June
April 8, 2026
-
ORGANIZATION Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
-
BUSINESS Japan Ethical Drug Sales Surge 7.7% in February: Crecon
April 8, 2026
-
COLUMN The Patient North Star: How Gilead Japan Redefined Innovation
April 8, 2026
-
REGULATORY Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
-
REGULATORY Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
-
REGULATORY Japan Identifies 28 New “Drug Loss” Products from 2021-23 Approvals
April 7, 2026
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
